Israeli millionaire aims to create an multi-feature online cannabis app

After years of unsuccessful attempts to market the drug ‘Stibax’ in Israel, an artificial imitation of cannabis, the Israeli tycoon David Forer, the owner of the pharmaceutical company Neopharm, announced this week that he had decided to enter the local cannabis market.

According to a report to the stock exchange, Forer will invest through Neopharm in establishing a new company, which should set up an app that will allow online ordering of medical cannabis, along with a delivery service – similar to applications in other leisure areas.

What will the app be called? This information has not been published, and has not yet been leaked, but for about a year now Forer and Neopharm have been trying to list the term ‘Dr. Cannabis’ as an exclusive trademark, apparently for this service.

Neopharm (37.5%) will share ownership of the new company, which will develop the app, with the new cannabis company ‘Intlicanna’ (37.5%), which is promoted by singer Aviv Geffen, and with Boris Mirkin (25%), former president of Russia’s communications division.

If you want to know more about cannabis, how he Israeli tycoon David Forer will start investing in the Israeli cannabis sector, and to find out the latest hemp news, download the Hemp.im mobile application.

Forer is ready to invest in the potential of the cannabis sector

Forer is one of Israel’s 100 richest people and is known as the “mystery man of the pharmaceutical industry.” He is considered one of the most connected businessmen within the Ministry of Health and is well connected to senior businessmen as well as politicians like Herzog, Livni, Barak Lieberman and more.

Tal Forer, David’s son, chief business officer at Neopharm, stated in a conversation with Calcalist that “the cannabis market has reached a critical mass and has become interesting for us, as it is expected to grow exponentially, so we want to take part in it.”

Although they have not yet marketed cannabis in reality, Intlicanna CEO, Uri Weiss, states that “Intlicanna has one of the most advanced and high-quality cannabis growing facilities established in Israel and grows unique cannabis strains, and we bring a logistics and operating platform.”

On the other hand, Weiss says that “we have no goal to become medical cannabis growers, but to focus on what we know to do best. The agreement with Neopharm will help us gain a broader market share. In fact, we have gained a competitive advantage over the older cannabis companies.”

The corporation is owned by Forer, which generates over $440 million (NIS 1.5 billion) a year, and in addition to Neopharm, it also includes companies in the field of drug distribution, such as Elden Equipment, Promedico, Dr. Ore and more.

Neopharm will focus on cannabis after failing with their last product

“Part of Neopharm’s goal for the near future is to push forward Stevax,” Forer said in 2012. “This drug has a lot of opponents, but as always, when I close the door I enter through the window.” Forer failed however in his attempt and will now try his luck with cannabis.

Dr. Segev Shani, VP of Medicine and Regulation at the Neopharm Group, also had something to say about cannabis. He claimed that “there is nothing to compare” between the plant and the drug, which consists of artificial cannabis ingredients. “Our product is a drug, with all due respect to marijuana,” he said.

Today, ‘Neopharm’ markets, among other things, Advil pills, Listerine mouthwashes, Similac, antidepressants, Abbott’s products, Pfizer, Novartis’ vaccines division and more. The drug ‘Stevax’, which was sold at huge prices, did not succeed in becoming a success.

Given that until a few years ago the most lucrative business in the legal cannabis market in the US was an app for ordering and shipping cannabis to home, if Forer succeeds in his plan he may also dominate a very significant portion of the Israeli cannabis market, and perhaps more.

__

(Featured image by GRAS GRÜN via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in קנאביס, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.